# Clinical Pharmacology Analytical Core

> **NIH NIH P30** · INDIANA UNIVERSITY INDIANAPOLIS · 2024 · $60,958

## Abstract

ABSTRACT, Clinical Pharmacology Analytical Core (CPAC)
The Indiana University Simon Comprehensive Cancer Center (IUSCCC) Clinical Pharmacology Analytical Core
(CPAC) provides multifaceted expertise in bioanalytical methodology and clinical pharmacology to provide
investigators with robust information including in vivo pharmacokinetics, drug-drug interactions, in vitro drug
metabolic stability, stereoselective metabolism, metabolite identification, formulation optimization, protein
binding, drug purity verification, and drug stability. CPAC's expertise in bioanalytical analysis is coupled with
state-of-the-art laboratory equipment including three UHPLC triple quadrupole QTRAP mass spectrometers (LC-
MS/MS QTRAP) for quantification of drugs and metabolites, two of which were recently purchased through a
collaboration of the IU School of Medicine and IUSCCC, one HPLC photo diode array system, LC-UV
technologies, and a Biomek 4000 liquid handling robot, all to facilitate the research and development of drugs
and new chemical entities. CPAC and IUSCCC's leadership have defined three specific aims for this Shared
Resource: Aim 1. Provide IUSCCC members with broad, high-quality small molecule bioanalytical services from
various matrices in expedited timelines; Aim 2. Facilitate cancer drug discovery and development research by
working closely with investigators and the Cancer Drug Discovery and Development Accelerator (CD3A) group
to establish effective lead generation and lead optimization strategies; and Aim 3. Provide detailed pre-clinical
and clinical data analysis, including non-compartmental and compartmental pharmacokinetic (PK) analysis and
pharmacokinetic/pharmacodynamic (PK/PD) modeling. Through these aims, CPAC has supported CD3A and
clinical investigators by providing cost-effective, validated assays to support in vitro and in vivo ADME and PK
analyses of small molecules. Over the past three years, CPAC has supported 32 IUSCC investigators on
numerous projects, with over 2200 service hours devoted to method development, formulation optimization,
solubility assessment, protein binding, and metabolic stability and analyte quantification in over 4000 tissue and
plasma samples. Over the next five years, it is anticipated that demand will continue to grow for these services
and expertise to support the growing number of preclinical drug development programs supported by CD3A and
advancement of candidate drug molecules towards clinical trials.

## Key facts

- **NIH application ID:** 10934651
- **Project number:** 2P30CA082709-25
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** Sara K Quinney
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $60,958
- **Award type:** 2
- **Project period:** 1999-09-22 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10934651

## Citation

> US National Institutes of Health, RePORTER application 10934651, Clinical Pharmacology Analytical Core (2P30CA082709-25). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10934651. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*